Evidence map›Paper›PMID 37155145›Full record

ArticleAging2023

Ling Zhi-8, a fungal immunomodulatory protein in

Ju-Pi Li, Ching-Liang Chu, Wan-Ru Chao, Cheng-Siang Yeh, Yi-Ju Lee, Dz-Chi Chen, Shun-Fa Yang, Yu-Hua Chao

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Immunomodulatory Effects ofCurrent issues in molecular biology · 2025
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ju-Pi LiDepartment of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
Ching-Liang ChuGraduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Wan-Ru ChaoSchool of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Cheng-Siang YehSchool of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Yi-Ju LeeSchool of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Dz-Chi ChenYeastern Biotech Co., Ltd., New Taipei City, Taiwan.
Shun-Fa YangDepartment of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
Yu-Hua ChaoDepartment of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
Chung Shan Medical University · TWChung Shan Medical University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CPT-11 (Irinotecan) remains an important chemotherapeutic agent against various solid tumors nowadays. Potential adverse effects, especially gastrointestinal toxicities, are the main limiting factor for its clinical utility. Ling Zhi-8 (LZ-8), a fungal immunomodulatory protein in

Indexed as

ReishiAnimalsClaudin-1IrinotecanMiceClaudin-1Irinotecanclaudin-1CPT-11Ganoderma lucidumirinotecanLing Zhi-8

Identifiers

PMID37155145
PMCPMC10449289
OpenAlexW4372279198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.